AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17453860
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg 17beta‐estradiol + 0.25 mg NETA
Trial: 15168036
Drug: Olive oils
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oils with increasing phenolic concentration (0 to 150 mg/Kg)
Trial: 12114917
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (3 doses, 800 microg each)
Trial: 10049275
Drug: Abacavir 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir 4 mg/kg
Trial: 10049275
Drug: Abacavir 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir 8 mg/kg
Trial: 10049275
Drug: Abacavir (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir (both doses)
Trial: 526385
Drug: Ketamine i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine i.v. infusion
Trial: 24519448
Drug: Cryotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy plus laser therapy (ice chips for 1 h 35 min followed by low-level laser therapy, InGaAIP, 660 nm, 40 mW, 6 J/cm(2), n = 54)
Trial: 24519448
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy alone (n = 17)
Trial: 24519448
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no specific treatment for OM, n = 33)
Trial: 23440253
Drug: Weekly volunteering
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly volunteering with elementary school‐aged children for 2 months
Trial: 10525745
Drug: Triple the
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple the maintenance dose every 72 h
Trial: 10525745
Drug: Double the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double the maintenance dose every 48 h
Trial: 10525745
Drug: Maintenance dose
RxNorm normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance dose every 24 h
Trial: 8546911
Drug: ICR62 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICR62 2.5 mg
Trial: 8546911
Drug: ICR62 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICR62 10 mg
Trial: 8546911
Drug: ICR62 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICR62 20 mg
Trial: 8546911
Drug: ICR62 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICR62 40 mg
Trial: 8546911
Drug: ICR62 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICR62 100 mg
Trial: 1884746
Drug: HR (2
RxNorm normalized name: Yttrium Y-90 n-((4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl)-d-phe-cys-tyr-d-trp-lys-thr-cys-thr (2-7)disulfide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR (2 tablets of 500 mg/day)
Trial: 6346476
Drug: Estradurin/Etivex (estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradurin/Etivex (estrogen preparation)
Trial: 27327283
Drug: Ranibizumab 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 1.0 mg
Trial: 27327283
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg and 1.0 mg
Trial: 22027845
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 150 mg/day
Trial: 22045039
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (150 and 300 mg/day)
Trial: 22045039
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR 150 mg/day and Escitalopram
Trial: 21146654
Drug: Standard activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard activated clotting time (ACT)-guided doses of intravenous UFH
Trial: 21146654
Drug: Non-ACT-guided weight-adjusted
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ACT-guided weight-adjusted low dose of intravenous UFH
Trial: 21146654
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (Standard and Low-dose)
Trial: 16282047
Drug: Conventional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatments for OA
Trial: 9499327
Drug: Thalidomide 300
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide 300 mg/d
Trial: 9499327
Drug: Thalidomide 100
RxNorm normalized name: thalidomide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 100 mg/d and 300 mg/d
Trial: 29190605
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of colistin
Trial: 29190605
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of colistin
Trial: 25622198
Drug: Concurrent smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent smoking cessation (CSC) intervention
Trial: 25622198
Drug: Daily assessments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily assessments during CSC
Trial: 31365529
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL of 4% articaine with 1:100,000 epinephrine
Trial: 31365529
Drug: 3.6 mL
RxNorm normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mL of 4% articaine with 1:100,000 epinephrine
Trial: 21246795
Drug: Cranberry extract
RxNorm normalized name: CRANBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry extract capsules (equiv. 17,000 mg of fresh fruit) taken twice a day, 4 days before and 5 days after surgery
Trial: 15058118
Drug: Prepared morphine
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepared morphine solution 10 mg (Group Ten)
Trial: 15058118
Drug: Prepared morphine
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepared morphine solution 5 mg (Group Five)
Trial: 15058118
Drug: Prepared morphine
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepared morphine solution (Group Ten and Group Five)
Trial: 11464349
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with bupivacaine (0.166%, 2 to 8 mL/h) and diamorphine (0.2 to 0.8 mg/h) for 24 hours before and during operation (14 patients)
Trial: 11464349
Drug: Intraoperative perineural
RxNorm normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative perineural catheter infusing bupivacaine (0.25%, 10 mL/h) (16 patients)
Trial: 7993161
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (verbal instructions and handout about medication)
Trial: 2910050
Drug: Intravenous indomethacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous indomethacin, 0.2 mg/kg per dose, three doses on the fourth day of life
Trial: 790351
Drug: Betahistine hydrochloride
RxNorm normalized name: Betahistine Hydrochloride
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine hydrochloride 32 mg daily for 16 weeks
Trial: 28616796
Drug: Bilateral topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral topical anesthetic eye drops (Group 2)
Trial: 28616796
Drug: Ipsilateral topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsilateral topical anesthetic eye drops (Group 1)
Trial: 28610898
Drug: Immediate insertion
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate insertion of levonorgestrel contraceptive implants (75 mg, 2-rod system) within 5 days of delivery
Trial: 28610898
Drug: Delayed insertion
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed insertion of levonorgestrel contraceptive implants (75 mg, 2-rod system) at 6 weeks postpartum
Trial: 28610898
Drug: Immediate insertion
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate insertion of levonorgestrel contraceptive implants
Trial: 21679246
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 250, 500, 1000, 1250 or 1500 mg of mildronate capsules
Trial: 21679246
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of 500 mg of mildronate capsules three times a day for 13 days
Trial: 17172616
Drug: Cumulative levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cumulative levodopa dose
Trial: 17172616
Drug: Cumulative levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cumulative levodopa equivalent dose (levodopa plus pramipexole)
Trial: 17172616
Drug: Cumulative levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cumulative levodopa equivalent dose
Trial: 14743580
Drug: Cholesterol-enriched lipid
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-enriched lipid emulsion (4 g/l free cholesterol)
Trial: 11070454
Drug: Formoterol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (12 microg) dry-powder inhalation
Trial: 1349492
Drug: abanoquil 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abanoquil 0.25 mg
Trial: 1349492
Drug: abanoquil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abanoquil 0.5 mg
Trial: 1349492
Drug: abanoquil 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abanoquil 1 mg
Trial: 30956216
Drug: Amiodarone prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone prophylaxis (150 mg IV bolus, followed by 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours)
Trial: 30015649
Drug: Couple-based interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple-based interventions addressing traditional cardiovascular risk factors; details on dosage and duration not available.
Trial: 30015649
Drug: Attachment-based interventions,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment-based interventions, such as the Healing Hearts Together program; details on dosage and duration not available.
Trial: 30015649
Drug: Couple-based interventions;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple-based interventions; details on dosage and duration not available.
Trial: 22574587
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (AD) 10 mg, once daily, combined with Baihua Xianglian Detoxification Recipe (BXDR) twice daily
Trial: 21240151
Drug: Quetiapine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine IR 800 mg/day
Trial: 12600115
Drug: Intravenous reduced
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous reduced glutathione (GSH) at a dose of 1200 mg twice a week for 12 weeks
Trial: 12600115
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant human erythropoietin (r‐HuEPO) at a dose of 3000U twice a week for 12 weeks
Trial: 7981015
Drug: Vinpocetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinpocetine (10 mg three times daily)
Trial: 7981015
Drug: Oxazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (10 mg three times daily)
Trial: 2597598
Drug: Inderex (bendrofluazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inderex (bendrofluazide 5 mg and Inderal LA 160 mg)
Trial: 2597598
Drug: Inderal LA
RxNorm normalized name: Inderal LA
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inderal LA (160 mg)
Trial: 6134137
Drug: Bendrofluazide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide (5 mg)
Trial: 30796762
Drug: Phytogenic plant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytogenic plant diets (various treatments)
Trial: 29805491
Drug: Intravenous corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous corticosteroid treatment (methylprednisolone)
Trial: 29805491
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid treatment (budesonide)
Trial: 27139820
Drug: Cabozantinib tablet
RxNorm normalized name: cabozantinib Oral Tablet
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib tablet formulation (140 mg)
Trial: 27139820
Drug: Cabozantinib tablet
RxNorm normalized name: cabozantinib Oral Tablet
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib tablet strengths (20, 40, and 60 mg)
Trial: 12040355
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (1/2 NS)
Trial: 12040355
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (1/2 NS) in patients with diabetes
Trial: 8625180
Drug: Three courses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three courses of postoperative COPAC chemotherapy followed by similar radiotherapy schedule (chemotherapy/radiotherapy group)
Trial: 6797085
Drug: Aerosol agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol agents (specific agents not detailed)
Trial: 6797085
Drug: Parasympathetic system
RxNorm normalized name: Bos taurus parasympathetic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parasympathetic system blocker
Trial: 27989690
Drug: Tadalafil (40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (40mg daily for six weeks)
Trial: 22586334
Drug: Smoked cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked cannabis (once daily for three days)
Trial: 22586334
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo cigarettes (once daily for three days)
Trial: 20853602
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside in high doses (first and second course)
Trial: 20853602
Drug: Aggressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive therapy
Trial: 20853602
Drug: Current AML
RxNorm normalized name: AML-2-23
DrugBank: AML-2-23 (DB17433)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current AML treatment programs
Trial: 17984737
Drug: Aminophylline (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (375 mg infusion)
Trial: 15338100
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with diazepam
Trial: 2091337
Drug: Artemisinine suppositories
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinine suppositories
Trial: 2091337
Drug: Oral quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quinine
Trial: 27662551
Drug: Oral pentavalent
RxNorm normalized name: rotavirus vacc, live oral pentavalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pentavalent rotavirus vaccine (RV5)
Trial: 23323672
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRI) added to supportive care
Trial: 17550491
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg vaginal misoprostol every six hours up to four doses
Trial: 17550491
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg vaginal misoprostol every six hours up to four doses
Trial: 10781464
Drug: Sufentanil 5
RxNorm normalized name: SUFentanil 50 MCG in 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 5 microg combined with midazolam 1 mg
Trial: 1550481
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate 90 minutes before surgery plus intraoperative neural blockade, with a postoperative analgesic regimen with combined bupivacaine hydrochloride‐morphine and indomethacin sodium (group 2)
Trial: 1550481
Drug: Conventional postoperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional postoperative pain treatment with morphine chloride and acetaminophen (group 1)
Trial: 2863443
Drug: Elective testicular
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective testicular biopsy during chemotherapy
Trial: 2863443
Drug: End-of-therapy testicular
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-of-therapy testicular biopsy
Trial: 27296243
Drug: Conversation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversation Therapy (CT)
Trial: 27296243
Drug: Stimulation Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation Therapy (ST)
Trial: 23688830
Drug: Clinician-guided Internet-delivered
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-guided Internet-delivered cognitive behaviour therapy (iCBT) program (the Pain Course) consisting of 5 lessons, homework tasks, additional resources, and weekly contact from a Clinical Psychologist.
Trial: 10023151
Drug: Polarizing mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polarizing mixture (potassium + insulin + glucose)
Trial: 8453222
Drug: Hypotonic ORS
RxNorm normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotonic ORS solution (224 mosmol/l)
Trial: 8453222
Drug: Isotonic ORS
RxNorm normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic ORS solution (304 mosmol/l)
Trial: 3020732
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement (MaxEPA) 15 gm per day
Trial: 31689510
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) with mechanical debridement (MD) (Group-A)
Trial: 31689510
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics (AB) with mechanical debridement (MD) (Group-B)
Trial: 30301642
Drug: Pre-vaccine Exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-vaccine Exercise (15-minutes upper body exercise)
Trial: 30301642
Drug: Pre-vaccine Arm,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-vaccine Arm, Pre-vaccine Leg, Post-vaccine Arm (15-minutes of arm or leg exercises)
Trial: 26510574
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy administered to the dorsum of the tongue
Trial: 26510574
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with a tongue scraper
Trial: 26510574
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with a tongue scraper combined with photodynamic therapy
Trial: 21564154
Drug: Exercise plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise plus usual treatment
Trial: 21335296
Drug: Community pharmacy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community pharmacy-based falls-prevention program (medication consultation)
Trial: 21335296
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication consultation)
Trial: 10321505
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg of leuprolide acetate every month
Trial: 10321505
Drug: 11.25 mg
RxNorm normalized name: phentermine 11.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.25 mg of leuprolide acetate every 3 months
Trial: 23943256
Drug: Conventional restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional restorative treatment (CRT) using amalgam